TMDX logo

TransMedics Group Inc. (TMDX)

$93.91

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TMDX

Market cap

$3.26B

EPS

3.66

P/E ratio

20.1

Price to sales

4.04

Dividend yield

--

Beta

2.126797

Price on TMDX

Previous close

$92.21

Today's open

$91.73

Day's range

$91.32 - $95.60

52 week range

$60.11 - $156

Profile about TMDX

CEO

Waleed H. Hassanein

Employees

898

Headquarters

Andover, MA

Exchange

NASDAQ Global Market

Shares outstanding

34733883

Issue type

Common Stock

TMDX industries and sectors

Healthcare

Medical Equipment & Supplies

News on TMDX

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

news source

PRNewsWire • Nov 12, 2026

news preview

TransMedics: 2027 Setting Up To Be A Pivotal Year

TransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart, DENOVO Lung, CHOPS, OCS Kidney, and European expansion, all critical for achieving ambitious transplant volume targets. Q3 2026 saw record $203M revenue (+41% YoY), with management raising 2026 guidance to $764–$774M and operating margins expected at 12.5%–14%.

news source

Seeking Alpha • Nov 11, 2026

news preview

TransMedics (TMDX) Just Reclaimed the 200-Day Moving Average

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 200-day moving average, which suggests a long-term bullish trend.

news source

Zacks Investment Research • Nov 10, 2026

news preview

TransMedics: Growth Is Accelerating Again And 2027 Looks Promising

TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins, and market share gains in the recent quarter. TransMedics raised full-year revenue guidance to $764-774 million, with organic growth of 24-26% and service revenue up 60% YoY. Key 2027 growth catalysts include European expansion, new heart and lung programs, and the early-stage kidney opportunity.

news source

Seeking Alpha • Nov 10, 2026

news preview

TransMedics: 3 Key Takeaways for Long-Term Investors

TransMedics raised 2026 revenue guidance to $764 million to $774 million. Third-quarter revenue reached $203 million, up 41% year over year.

news source

The Motley Fool • Nov 10, 2026

news preview

TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 20-day moving average, which suggests a short-term bullish trend.

news source

Zacks Investment Research • Nov 9, 2026

news preview

TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average

From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

news source

Zacks Investment Research • Nov 9, 2026

news preview

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. deceased donor volume.

news source

MarketBeat • Nov 6, 2026

news preview

Unusual Options Volume Report: 3 Stocks Moving After Earnings

Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).

news source

Schaeffers Research • Nov 6, 2026

news preview

Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 400 points on Friday.

news source

Benzinga • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in TransMedics Group Inc.

Open an M1 investment account to buy and sell TransMedics Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TMDX on M1